Nigella sativa oil affects glucose metabolism and lipid concentrations in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial

被引:70
|
作者
Heshmati, Javad [1 ]
Namazi, Nazli [2 ]
Memarzadeh, Mohammad-Reza [3 ]
Taghizadeh, Mohsen [3 ]
Kolandooz, Fariba [4 ]
机构
[1] Kermanshah Univ Med Sci, Hlth Care Ctr, Kermanshah, Iran
[2] Tabriz Univ Med Sci, Fac Nutr, Nutr Res Ctr, Tabriz, Iran
[3] Barij Essence Pharmaceut Co, Ctr Res & Dev, Kashan, Iran
[4] Univ Alberta, Dept Med, Fac Med & Dent, Aboriginal & Global Hlth Res Grp, Edmonton, AB, Canada
关键词
Nigella sativa; Blood glucose; Dyslipidemias; Diabetes mellitus; Type; 2; MEDICINAL-PLANTS; URTICA-DIOICA; SEED EXTRACT; THYMOQUINONE; PEROXIDATION; PROFILE;
D O I
10.1016/j.foodres.2015.01.030
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
The aim of the present study was to determine the effects of Nigella sativa (NS) oil on glucose metabolism and lipid concentrations in patients with type 2 diabetes (T2DM). In this double-blind randomized controlled clinical trial, 72 volunteer subjects at Endocrinology Clinics of Kermanshah were recruited. Participants were patients aged 30-60 years old with T2DM. They were randomly divided into intervention (n = 36) and placebo groups (n = 36) and received 3 g/day (one three times a day) NS oil or sunflower soft gel capsules for 12 weeks. At baseline and at the end of the trial, anthropometric indices, dietary intake and biochemical parameters were measured. Sixty-seven patients completed the trial (intervention n = 34, placebo n = 33). Since the data analysis was based on intention-to-treat approach, all 72 subjects (36 in each group) were included for data analysis. Two groups were similar in the baseline characteristics. After the intervention, weight and body mass index decreased in the intervention group compared to the baseline, but it was not significant between the two groups. Dietary intake in both groups changed compared to baseline. Comparison of the two groups indicated that fasting blood sugar, glycated hemoglobin, triglyceride and low density lipoprotein-cholesterol changed significantly in intervention group compared to the placebo group (p < 0.05, adjusted for confounder factors). Insulin level and insulin resistance decreased and high density lipoprotein-cholesterol increased in the intervention group, but after adjusting for confounder factors, they were not significant. Supplementation with NS oil can improve glycemic status and lipid profile in patients with T2DM. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 50 条
  • [11] Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial
    Douek, IF
    Allen, SE
    Ewings, P
    Gale, EAM
    Bingley, PJ
    DIABETIC MEDICINE, 2005, 22 (05) : 634 - 640
  • [12] Efficacy of Nigella sativa seeds oil in patients with Behcet's disease: a double-blind randomized controlled trial
    Kavandi, Hadiseh
    Hajialilo, Mehrzad
    Khabbazi, Alireza
    AVICENNA JOURNAL OF PHYTOMEDICINE, 2018, 8 (06) : 498 - 503
  • [13] Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial
    Heo, Ji Hye
    Han, Kyung Ah
    Hong, Jun Hwa
    Seo, Hyun-Ae
    Hong, Eun-Gyoung
    Yu, Jae Myung
    Jung, Hye Seung
    Cha, Bong-Soo
    DIABETES & METABOLISM JOURNAL, 2024, 48 (05) : 937 - 948
  • [14] Effects of Nigella sativa oil extract on inflammatory cytokine response and oxidative stress status in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial
    Hadi, Vahid
    Kheirouri, Sorayya
    Alizadeh, Mohammad
    Khabbazi, Alireza
    Hosseini, Hossein
    AVICENNA JOURNAL OF PHYTOMEDICINE, 2016, 6 (01) : 34 - 43
  • [15] Effects of Nigella sativa oil supplementation on selected metabolic parameters and anthropometric indices in patients with coronary artery disease: A randomized, double-blind, placebo-controlled clinical trial
    Tavakoli-Rouzbehani, Omid Mohammad
    Abbasnezhad, Mohsen
    Kheirouri, Sorayya
    Alizadeh, Mohammad
    PHYTOTHERAPY RESEARCH, 2021, 35 (07) : 3988 - 3999
  • [16] Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial
    Ji, Linong
    Lu, Jinmiao
    Gao, Leili
    Ying, Changjiang
    Sun, Jiao
    Han, Jie
    Zhao, Wenhua
    Gao, Yunming
    Wang, Kun
    Zheng, Xin
    Xie, Daosheng
    Ding, Juping
    Zhao, Jiahong
    Yu, Qiang
    Wang, Tong
    DIABETES OBESITY & METABOLISM, 2023, 25 (12) : 3671 - 3681
  • [17] The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial
    Seyyedebrahimi, ShadiSadat
    Khodabandehloo, Hadi
    Esfahani, Ensieh Nasli
    Meshkani, Reza
    ACTA DIABETOLOGICA, 2018, 55 (04) : 341 - 353
  • [18] Effects of Tarragon Powder on Glucose Metabolic Changes, Lipid Profile and Antioxidant Enzyme Levels in Type 2 Patients with Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial
    Haghighian, Hossein Khadem
    Shiran, Mohammadreza
    Akha, Ozra
    Ghafouri, Zahra
    Ghaedi, Ehsan
    Bayat, Sara
    Mazloomi, Mohammad Ali
    Houshmand, Gholamreza
    JUNDISHAPUR JOURNAL OF NATURAL PHARMACEUTICAL PRODUCTS, 2021, 16 (01)
  • [19] The effects of astaxanthin on AMPK/autophagy axis and inflammation in type 2 diabetes patients: A randomized, double-blind, placebo-controlled trial
    Sharifi-Rigi, Ali
    Zal, Fatemeh
    Aarabi, Mohammad-Hossein
    Rad, Nikoo Roustaei
    Naghibalhossaini, Fakhraddin
    Shafiee, Seyed Mohammad
    Aminorroaya, Ashraf
    GENE REPORTS, 2023, 33
  • [20] Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial
    Liakos, Aris
    Lambadiari, Vaia
    Bargiota, Alexandra
    Kitsios, Konstantinos
    Avramidis, Iakovos
    Kotsa, Kalliopi
    Gerou, Spyridon
    Boura, Panagiota
    Tentolouris, Nikolaos
    Dimitriadis, George
    Tsapas, Apostolos
    DIABETES OBESITY & METABOLISM, 2019, 21 (03) : 517 - 524